Celldex Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Celldex Therapeutics is Anthony Marucci, benoemd in May2003, heeft een ambtstermijn van 21.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.36M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.061% van de aandelen van het bedrijf, ter waarde € 1.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.4 jaar en 11.8 jaar.

Belangrijke informatie

Anthony Marucci

Algemeen directeur

US$8.4m

Totale compensatie

Percentage CEO-salaris	8.6%
Dienstverband CEO	21.5yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	8.4yrs
Gemiddelde ambtstermijn bestuur	11.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Anthony Marucci's beloning veranderd ten opzichte van Celldex Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$154m
Jun 30 2024	n/a	n/a	-US$150m
Mar 31 2024	n/a	n/a	-US$145m
Dec 31 2023	US$8m	US$721k	-US$141m
Sep 30 2023	n/a	n/a	-US$125m
Jun 30 2023	n/a	n/a	-US$113m
Mar 31 2023	n/a	n/a	-US$119m
Dec 31 2022	US$5m	US$693k	-US$112m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$100m
Mar 31 2022	n/a	n/a	-US$77m
Dec 31 2021	US$6m	US$669k	-US$71m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$66m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$3m	US$644k	-US$60m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$46m
Dec 31 2019	US$1m	US$619k	-US$51m
Sep 30 2019	n/a	n/a	-US$50m
Jun 30 2019	n/a	n/a	-US$46m
Mar 31 2019	n/a	n/a	-US$50m
Dec 31 2018	US$1m	US$608k	-US$151m
Sep 30 2018	n/a	n/a	-US$146m
Jun 30 2018	n/a	n/a	-US$165m
Mar 31 2018	n/a	n/a	-US$177m
Dec 31 2017	US$2m	US$598k	-US$93m

Compensatie versus markt: De totale vergoeding ($USD 8.36M ) Anthony } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.63M ).

Compensatie versus inkomsten: De vergoeding van Anthony is gestegen terwijl het bedrijf verliesgevend is.

CEO

Anthony Marucci (62 yo)

21.5yrs

Tenure

US$8,361,844

Compensatie

Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Marucci	Founder	21.5yrs	US$8.36m	0.061% € 1.0m
Tibor Keler	Founder	21.5yrs	US$3.42m	0.011% € 185.3k
Sam Martin	Senior VP	7.3yrs	US$2.95m	0.042% € 708.1k
Margo Heath-Chiozzi	Senior Vice President of Regulatory Affairs	7.1yrs	US$2.94m	0.020% € 336.9k
Diane Young	Senior VP & Chief Medical Officer	5.4yrs	US$2.97m	0.026% € 431.0k
Joseph Schlessinger	Co-Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration	7.4yrs	geen gegevens	0.0028% € 46.8k
Freddy Jimenez	Senior VP & General Counsel	3.8yrs	US$2.17m	0.053% € 892.9k
Ronald Pepin	Chief Business Officer & Senior VP	13.3yrs	geen gegevens	geen gegevens
Elizabeth Crowley	Chief Product Development Officer & Senior VP	10.3yrs	US$1.18m	0.014% € 228.5k
Richard Wright	Chief Commercial Officer & Senior VP	9.3yrs	US$563.17k	0.031% € 524.5k

8.4yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TCE2 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Marucci	Founder	15.9yrs	US$8.36m	0.061% € 1.0m
Joseph Schlessinger	Co-Founder & Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Harry Penner	Independent Director	27.8yrs	US$371.19k	0.0042% € 70.3k
Herbert Conrad	Independent Director	16.7yrs	US$364.94k	0.0039% € 64.5k
Louis Weiner	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Marino	Independent Director	7.7yrs	US$377.44k	0.0033% € 55.5k
Karen Shoos	Independent Chair of the Board of Directors	23.5yrs	US$385.77k	0.0042% € 70.2k
Carl June	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michel Nussenzweig	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Marc Rothenberg	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Keith Brownlie	Independent Director	7.4yrs	US$373.27k	0.0010% € 16.7k
Cheryl Cohen	Independent Director	2.4yrs	US$367.02k	0% € 0

11.8yrs

Gemiddelde duur

72yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TCE2 zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.8 jaar).

Celldex Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Founder recently bought €290k worth of stock

Senior VP & Chief Medical Officer recently sold €1.5m worth of stock

Senior VP recently sold €314k worth of stock

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics, Inc. Announces Board Appointments

Recent updates

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought €290k worth of stock

Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.81 loss in 3Q 2023)

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.65 loss in 2Q 2023)

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

New minor risk - Share price stability

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Senior VP & Chief Medical Officer recently sold €1.5m worth of stock

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold €314k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.62 loss in 1Q 2023)

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings released: US$2.92 loss per share (vs US$2.40 loss in FY 2022)

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2022)

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.77 loss in 2Q 2022)

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Now 22% undervalued after recent price drop

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.49 loss in 1Q 2022)

Full year 2022 earnings released: US$2.40 loss per share (vs US$1.65 loss in FY 2021)

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Second quarter 2022 earnings released: US$0.77 loss per share (vs US$0.34 loss in 2Q 2021)

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces Board Appointments

First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.36 loss in 3Q 2020)

Celldex Therapeutics, Inc. Announces Initiation of CDX-0159 Subcutaneous Formulation Study

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.50 loss in 2Q 2020)

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial

Celldex Therapeutics, Inc. Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

First quarter 2021 earnings released: US$0.42 loss per share (vs US$0.72 loss in 1Q 2020)

Celldex Provides Reports Impairment for the Fourth Quarter of 2020

Full year 2020 earnings released: US$2.02 loss per share (vs US$3.51 loss in FY 2019)

New 90-day high: €24.00

Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)

New 90-day high: €20.00

Celldex Therapeutics, Inc. Promotes Freddy Jimenez, to the Newly Created Position of Senior Vice President and General Counsel

Celldex Therapeutics, Inc. Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

New 90-day high: €19.13

Celldex Therapeutics, Inc. Initiates Phase 1B Study of Cdx-0159 in Chronic Spontaneous Urticaria